rolipram has been researched along with Pulmonary Hypertension in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "1% when administered intravenously at 30 microg/kg to the chronically hypoxic rats and had an apparent oral bioavailability of about 19." | 1.31 | 4-(3-Chloro-4-methoxybenzyl)aminophthalazines: synthesis and inhibitory activity toward phosphodiesterase 5. ( Adachi, H; Ishibashi, K; Ishihara, H; Kabasawa, Y; Kakiki, M; Kodama, K; Matsukura, M; Miyazaki, K; Nishino, M; Ozaki, H; Takase, Y; Watanabe, N, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Watanabe, N | 1 |
| Adachi, H | 1 |
| Takase, Y | 1 |
| Ozaki, H | 1 |
| Matsukura, M | 1 |
| Miyazaki, K | 1 |
| Ishibashi, K | 1 |
| Ishihara, H | 1 |
| Kodama, K | 1 |
| Nishino, M | 1 |
| Kakiki, M | 1 |
| Kabasawa, Y | 1 |
| De Franceschi, L | 1 |
| Platt, OS | 1 |
| Malpeli, G | 1 |
| Janin, A | 1 |
| Scarpa, A | 1 |
| Leboeuf, C | 1 |
| Beuzard, Y | 1 |
| Payen, E | 1 |
| Brugnara, C | 1 |
| Schermuly, RT | 2 |
| Ghofrani, HA | 2 |
| Enke, B | 1 |
| Weissmann, N | 2 |
| Grimminger, F | 2 |
| Seeger, W | 2 |
| Schudt, C | 2 |
| Walmrath, D | 2 |
| Roehl, A | 1 |
| Tenor, H | 1 |
| Champion, HC | 1 |
| Bivalacqua, TJ | 1 |
| Toyoda, K | 1 |
| Heistad, DD | 1 |
| Hyman, AL | 1 |
| Kadowitz, PJ | 1 |
5 other studies available for rolipram and Pulmonary Hypertension
| Article | Year |
|---|---|
4-(3-Chloro-4-methoxybenzyl)aminophthalazines: synthesis and inhibitory activity toward phosphodiesterase 5.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Antihypertensive Agents; Biological Availability; Bloo | 2000 |
Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice.
Topics: Anemia, Sickle Cell; Animals; Disease Models, Animal; Hypertension, Pulmonary; Hypoxia; Mice; Mice, | 2008 |
Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Administration, Inhalation; Aero | 1999 |
Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Aerosols; Animals; Antihypertens | 2000 |
In vivo gene transfer of prepro-calcitonin gene-related peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in the mouse.
Topics: Adenoviridae; Adrenomedullin; Animals; beta-Galactosidase; Calcitonin Gene-Related Peptide; Cyclic A | 2000 |